诊断学理论与实践

诊断学理论与实践 >

2024 , Vol. 23 >Issue 04: 439 - 444

DOI: https://doi.org/10.16150/j.1671-2870.2024.04.013

综述

18F-FDG PET/CT在滤泡性淋巴瘤诊断和预后评估中的研究进展

  • 李卓含 ,
  • 黄新韵 ,
  • 郭睿 ,
  • 李彪
展开
  • 1.山西医科大学医学科学院，山西 太原 030001
    2.上海交通大学医学院附属瑞金医院核医学科，上海 200025
李彪 E-mail: lb10363@rjh.com.cn

收稿日期: 2023-07-19

  录用日期: 2023-10-12

  网络出版日期: 2024-08-25

基金资助

上海申康医院发展中心临床科技创新项目(SHDC22023201)

收起

18F-FDG PET/CT in the diagnosis and prognosis evaluation of follicular lymphoma

  • LI Zhuohan ,
  • HUANG Xinyun ,
  • GUO Rui ,
  • LI Biao
Expand
  • 1. Academy of Medical Sciences, Shanxi Medical University, Taiyuan 030001, China
    2. Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2023-07-19

  Accepted date: 2023-10-12

  Online published: 2024-08-25

Fold

摘要

滤泡性淋巴瘤（follicular lymphoma, FL）是一种生物学性质复杂、临床表现异质性大的非霍奇金淋巴瘤，多累及全身淋巴结。我国约有7%的FL患者会发生组织学转化。转化为其他侵袭性淋巴瘤，因此不同FL患者的治疗策略及预后均存在较大差异。随着分子影像学技术的发展，PET/CT融合分子影像检查既能更精确识别体内微小病变又能提供病灶代谢信息。多项研究和指南均肯定了18氟-氟代脱氧葡萄糖-正电子发射断层扫描 (18F-fluorodeoxyglucose-positron emission computed tomography, 18F-FDG PET/CT)图像特征在FL识别诊断、分级分期、评价疗效和预测生存结局等过程中的重要价值。但由于尚无统一的图像扫描和阈值界定标准，目前在不同研究中PET/CT参数对FL患者具体的预后效能尚存在争议。本文综述了近年来国内外基于PET/CT图像特征，在早期识别高危FL患者及预测FL患者预后中的最新研究进展，进一步肯定了18F-FDG PET/CT检查在判断FL患者发生组织学转化的可能性以及评估其生存结局中的价值，旨在辅助临床优化诊疗决策，提高和改善患者的治疗效率和预后结局。

关键词： 滤泡性淋巴瘤; 正电子发射断层扫描; 预后; 诊断; 人工智能

本文引用格式

李卓含 , 黄新韵 , 郭睿 , 李彪 . 18F-FDG PET/CT在滤泡性淋巴瘤诊断和预后评估中的研究进展[J]. 诊断学理论与实践, 2024 , 23(04) : 439 -444 . DOI: 10.16150/j.1671-2870.2024.04.013

Abstract

Follicular lymphoma (FL) is a non-Hodgkin lymphoma with complex biological properties and heterogeneous clinical manifestations. FL mainly involves lymph nodes throughout the body, and about 7% of patients in China will histologically transform into other aggressive lymphoma. Therefore, there are great differences in the treatment strategies and prognosis of patients with FL. With the development of molecular imaging technology, PET/CT fusion molecular ima-ging can not only identify small lesions in vivo more accurately, but also provide metabolic information of lesions. A number of studies and guidelines have affirmed the important value of 18F-fluorodeoxyglucose-positron emission computed tomography (18F-FDG PET/CT) image features in the whole process of FL disease diagnosis, grading and staging, evaluation of efficacy and prediction of survival outcomes. However, due to the lack of uniform standards for image scanning and threshold definition, the specific prognostic efficacy of PET/CT parameters in FL patients in different studies is still controversial. This article reviews the recent progress in early identification of high-risk follicular lymphoma patients and prognosis prediction of FL patients based on PET/CT image features at home and abroad, further affirms the value of 18F-FDG PET/CT in judging the possibility of histological transformation of FL and evaluating the survival outcome of FL patients. To assist to optimize the clinical diagnosis and treatment decisions, improve the treatment efficiency and prognosis of FL patients.

Key words： Follicular lymphoma; Positron emission computed tomography; Prognosis; Diagnosis; Artificial intelligence

参考文献

[1] Cerhan J R. Epidemiology of Follicular Lymphoma[J]. Hematol Oncol Clin North Am, 2020, 34(4):631-646.
[2] ZHA J, FAN L, YI S, et al. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China[J]. J Hematol Oncol, 2021, 14(1):131.
[3] LI H, WANG M, ZHANG Y, et al. Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT[J]. Front Oncol. 2022; 12:943151.
[4] MEIGNAN M, COTTEREAU A S, VERSARI A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies[J]. J Clin Oncol, 2016, 34(30):3618-3626.
[5] DíAZ-SILVáN A, OTóN-SáNCHEZ L F, CARESIA-ARóZTEGUI A P, et al. Clinical application of [18F]FDG PET/CT in follicular lymphoma[J]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2022, 41(3):202-212.
[6] 张欢, 胡斌, 何柳, 等. 基线18F-FDG PET/CT显像在滤泡性淋巴瘤分布、分级和分期中的价值[J]. 现代肿瘤医学, 2023, 31(13):2496-2501.
  ZHANG H, HU B, HE L, et al. The value of baseline 18F-FDG PET/CT imaging in the distribution,grading and staging of follicular lymphoma[J]. Mod Oncol, 2023, 31: 2496-2501.
[7] 中华医学会核医学分会. 淋巴瘤18F-FDG PET/CT及PET/MR显像临床应用指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(3):161-169.
  Chinese Society of Nuclear Medicine. Clinical practice guideline of 18F-FDG PET/CT and PET/MR in lymphoma (2021 edition)[J]. Chin J Nucl Med Imaging, 2021, 41(3):161-169.
[8] KUROKI W, KITADATE A, ISHIYAMA K, et al. High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma[J]. Int J Hematol, 2022, 116(5):712-722.
[9] EL-GALALY T C, VILLA D, CHEAH C Y, et al. Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?[J]. Br J Haematol, 2022, 197(2):139-155.
[10] 中国抗癌协会淋巴瘤专业委员会, 中华医学会血液学分会. 中国滤泡性淋巴瘤诊断与治疗指南(2020年版)[J]. 中华血液学杂志, 2020, 41(7):537-544.
  Chinese Society of Lymphoma, Chinese Anti-cancer Association; Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of follicular lymphoma (2020)[J]. Chin J Hematol, 2020, 41(7):537-544.
[11] RODIER C, KANAGARATNAM L, MORLAND D, et al. Risk factors of progression in low-tumor burden follicular lymphoma initially managed by watch and wait in the era of PET and rituximab[J]. Hemasphere, 2023, 7(5):e861.
[12] LECCISOTTI L, MACCORA D, MALAFRONTE R, et al. Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden[J]. J Cancer Res Clin Oncol, 2023, 149(7):2783-2791.
[13] YANG Q, LUO Y, ZHANG Y, et al. Baseline [18F]FDG PET/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial “watch-and-wait” approach[J]. Eur Radiol, 2022, 32(8):5568-5576.
[14] DREVAL K, HILTON L K, CRUZ M, et al. Genetic subdivisions of follicular lymphoma defined by distinct co-ding and noncoding mutation patterns[J]. Blood, 2023, 142(6):561-573.
[15] STEUSSY B, LEKOSTAJ J, QIAN Q, et al. Leukemic transdifferentiation of follicular lymphoma into an acute histiocytic leukemia in a 52-year-old caucasian woman[J]. Lab Med, 2016, 47(2):155-157.
[16] 林志娟, 查洁, 易树华, 等. 伴弥漫大B细胞成分的初诊滤泡淋巴瘤患者的临床特征及生存[J]. 中华血液学杂志, 2022, 43(6):456-462.
  LIN Z J, ZHA J, YI S H, et al. Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component[J]. Chin J Hematol, 2022, 43(6):456-462.
[17] SCH?DER H, NOY A, G?NEN M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol, 2005, 23(21):4643-4651.
[18] RAJAM?KI A, KUITUNEN H, SORIGUE M, et al. FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma. Cancer Med. 2023; 12(1):407-411.
[19] MIR F, BARRINGTON S F, BROWN H, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study[J]. Blood, 2020, 135(15):1214-1218.
[20] LIPPI M, GIANOTTI S, FAMA A, et al. Texture analysis and multiple-instance learning for the classification of malignant lymphomas[J]. Comput Methods Programs Biomed, 2020, 185:105153.
[21] DE JESUS F M, YIN Y, MANTZOROU-KYRIAKI E, et al. Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET/CT features[J]. Eur J Nucl Med Mol Imaging, 2022, 49(5):1535-1543.
[22] KO?AK B, DURMAZ E ?, ATE? E, et al. Radiomics with artificial intelligence: a practical guide for beginners[J]. Diagn Interv Radiol, 2019, 25(6):485-495.
[23] LIANG J H, ZHANG Y P, XIA J, et al. Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma[J]. Cancer Res Treat, 2019, 51(4):1479-1487.
[24] ZHOU Y, ZHAO Z, LI J, et al. Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma[J]. Cancer Manag Res, 2019, 11:6871-6885.
[25] COTTEREAU A S, NIOCHE C, DIRAND A S, et al. 18F-FDG PET dissemination features in diffuse large b-cell lymphoma are predictive of outcome[J]. J Nucl Med, 2020, 61(1):40-45.
[26] EERTINK J J, VAN DE BRUG T, WIEGERS S E, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3):932-942.
[27] COTTEREAU A S, MEIGNAN M, NIOCHE C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT?[J]. Ann Oncol, 2021, 32(3):404-411.
[28] ZEMAN M N, AKIN E A, MERRYMAN R W, et al. Interim FDG-PET/CT for response assessment of lymphoma[J]. Semin Nucl Med, 2023, 53(3):371-388.
[29] JóNA á, KENYERES A, BARNA S, et al. Clinical and biological prognostic factors in follicular lymphoma patients[J]. PLoS One, 2022, 17(8):e0272787.
[30] SUN N, QIAO W, XING Y, et al. Prognostic value of interim 18F-FDG PET/CT in adult follicular lymphoma treated with R-CHOP[J]. Ann Hematol, 2023, 102(4):795-800.
[31] BOO S H, O J H, KWON S J, et al. Predictive value of interim and end-of-therapy 18F-FDG PET/CT in patients with follicular lymphoma[J]. Nucl Med Mol Imaging, 2019, 53(4):263-269.
[32] TATSUMI M, ISOHASHI K, MATSUNAGA K, et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma[J]. Int J Clin Oncol, 2019, 24(10):1292-1300.
[33] DEL PUIG CóZAR-SANTIAGO M, GARCíA-GARZóN J R, MORAGAS-FREIXA M, et al. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study. Optimización de los criterios metabólicos en la valoración pronóstica de los pacientes con linfoma. Estudio multicéntrico[J]. Rev Esp Med Nucl Imagen Mol, 2017, 36(5):304-311.
[34] SIBILLE L, SEIFERT R, AVRAMOVIC N, et al. 18F-FDG PET/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks[J]. Radiology, 2020, 294(2):445-452.
[35] BLANC-DURAND P, JéGOU S, KANOUN S, et al. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5):1362-1370.
[36] GIRUM K B, REBAUD L, COTTEREAU A S, et al. 18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients[J]. J Nucl Med, 2022, 63(12):1925-1932.
[37] 刘娟, 颜希月, 张亚平, 等. 18F-FDG PET/CT在黏膜相关淋巴组织淋巴瘤中的预测价值[J]. 中国临床研究, 2022, 35 (05): 649-654.
  LIU J, YAN X Y, ZHANG Y P, et al. Predictive value of 18F-FDG PET/CT in mucosa---associated lymphoid tissue lymphoma[J]. Chin J Clin Res, 2022, 35(5): 649-654.
[38] 王龙胜. 肺黏膜相关淋巴组织淋巴瘤的CT诊断——2023年读片窗(3) [J]. 安徽医学, 2023, 44(03): 361-362.
  WANG L S. CT diagnosis of pulmonary mucosal associated lymphoid tissue lymphoma ---2023 reading window (3)[J]. 2023, 44(03): 361-362.
Options
文章导航

/

〈 〉